Chat window
- Move between items in the chat window
- Tab key
- Shift + tab key
- Do action
- Enter key
This call is now closed. New applications can be submitted here.
The amount of funding presumed available for this call for proposals has been increased with NOK 5 million. The new amount presumed available is NOK 40 million.
We have updated the call with the ESA reference number
Commercialisation projects are intended to contribute to increased commercial use of publicly funded research.
The purpose of a qualification project is to carry out initial investigations into possible areas of commercial potential, which form the basis for further choices, including further directions of research, technology development and strategic decisions. The results from a completed qualification project can be used to support an application for further commercialisation through a proof-of-concept project, which could be the next step in bringing research results closer to a market-ready product or solution.
On our information page about Commercialisation Projects you will find useful practical information, frequently asked questions, examples of project and more.
The process of commercialising research results is often a long and complex journey towards a possible market. In Norway, funding agencies offer support for various phases of maturity in the process of commercialising research results.
Through the commercialisation instruments Qualification and Verification, the Research Council offers support for the pre-commercial phase, from research results to technology verification. Horizon Europe offers similar instruments through Proof-of-concept (ERC Pillar I) and Transition (EIC Pillar III).
Research results often form the basis for several possible commercial applications. The aim of a qualification project is to explore and identify the most promising commercial application possibilities. This involves preliminary commercial investigations, which forms the basis for further technology verification and development.
Once the application possibilities have been clarified, the next step in the process is to verify the technology according to its intended commercial use. This can be done through a verification project, to ensure the viability of the technology in a future market.
The pre-commercial phase is often characterised by close cooperation between academic and research environments, at the same time it is also essential to have an active dialogue with market participants and potential funders. This may include private investors, partners, licensees, etc. The goal is to define and achieve clear milestones that can trigger further funding after the technology has been verified.
Commercialisation support is intended to contribute to increased commercial use of publicly funded research. To qualify for such funding, projects must originate from approved Norwegian research organisations and must not have previously received commercialisation support from the Research Council.
Typical characteristics of a qualification project
The call is open to all thematic areas, and the project may be at TRL level 2–7 (Technology readiness level – the scale used in the EU).
Project duration can be from three to twelve months. The call for proposals is "ongoing" without a deadline, which means that once the application has been submitted via "My RCN Web", it will no longer be possible to make changes. Applications will be assessed and approved on an ongoing basis. You will receive an answer to your application as soon as possible (normally five to six weeks), but no later than three months after you have submitted your application. The earliest permitted project start-up is the day after the application has been submitted.
The call is available in both Norwegian and English. The Norwegian call text is legally binding.
The following actors may serve as applicants:
The Project Owner organisation must be one of the following:
Research organisation
The call is open to approved Norwegian research organisations. See here for the list of approved Norwegian research organisations.
Technology Transfer Office
The research organisation that owns the intellectual property rights must be a partner in the project.
Start-ups
For more information, see 'Conditions for funding' below.
The organisation listed as the Project Owner in the application form must have approved the project manager submitting the grant application.
Examples of projects that must involve partners:
On our website you will find more information about collaboration agreements and the use of subcontractors.
You can apply for funding to cover up to 100 per cent of the budgeted project costs.
Project costs are actual costs that are necessary to carry out the project. Please note that the item "Procurement of R&D services" is not to be used in this call. The type of costs must be entered as other operating expenses in the application form.
Typical activities include
The following are examples of costs that cannot be included in project costs:
Detailed and important information about What to enter into the budget can be found on the website and in our Guidelines for completing the application form that have been specifically prepared for commercialisation applications.
Our allocation of the grant rests on the allocation of funding for commercialisation to the Research Council over the state budget.
Research organisations and TTOs
Approved Norwegian research organisations, the TTOs representing these and any partners that are to receive support must satisfy the definition of a research and knowledge transfer organisation set out in the state aid rules. Any other partners will not be eligible to receive support from the Research Council for these projects.
Definition of research and knowledge dissemination organisation in the state aid rules:
an entity (such as universities or research institutes, technology transfer agencies, innovation intermediaries, research-oriented physical or virtual collaborative entities), irrespective of its legal status (organised under public or private law) or way of financing, whose primary goal is to independently conduct fundamental research, industrial research or experimental development or to widely disseminate the results of such activities by way of teaching, publication or knowledge transfer. Where such entity also pursues economic activities, the financing, the costs and the revenues of those economic activities must be accounted for separately. Undertakings that can exert a decisive influence upon such an entity, for example in the quality of shareholders or members, may not enjoy a preferential access to the results generated by it.
Funding awarded to research organisations or their affiliated TTOs may only be used to cover project costs related to activities of a non-economic character in the form of knowledge-transfer activities, as described in Item 19(b) of the EFTA Surveillance Authority’s guidelines on state aid for research and development and innovation.
Applicants must ensure that there is no indirect support for partner companies, for example in the form of favourably priced rights to results. The collaboration agreement must ensure that rights to results are distributed in accordance with item 29 of the EFTA Surveillance Authority's guidelines on state aid for research and development and innovation.
What is knowledge transfer activity?
In order to be considered part of the research organisation's non-economic activity, the knowledge-transfer activity must, in accordance with the EFTA Surveillance Authority's guidelines, either be carried out by the research organisation itself or in cooperation with or on behalf of other such entities.
The term knowledge transfer is defined as follows in the EFTA Surveillance Authority's guidelines on state aid for R&D:
"knowledge transfer" means any process which has the aim of acquiring, collecting and sharing explicit and tacit knowledge, including skills and competence in both economic and non-economic activities such as research collaborations, consultancy, licensing, spin-off creation, publication and mobility of researchers and other personnel involved in those activities. Besides scientific and technological knowledge, it includes other kinds of knowledge such as knowledge on the use of standards and regulations embedding them and on conditions of real-life operating environments and methods for organisational innovation, as well as management of knowledge related to identifying, acquiring, protecting, defending and exploiting intangible assets.
All profits from knowledge-transfer activities must also be reinvested in the primary activities of the research organisation. In that case, the support for knowledge-transfer activities does not constitute state aid. It is important to note that the activities do not lose their non-economic nature as third parties provide these services through open tenders.
We assume that the necessary separation of accounts for the research organisation's/TTO's economic and non-economic activities is in place.
See more on our information page: Conditions for awarding state aid.
Start-ups
Start-ups must be aware that the aid is awarded as state aid pursuant to Article 22 of the General Block Exemption Regulation for state aid (Commission Regulation (EU) No 651/2014 of 17 June 2014).
Allocation of funds is to be practised in accordance with the state aid rules. Conditions and concepts are to be interpreted in keeping with corresponding conditions and concepts in the state aid rules. If there is conflict between the text of the call and the state aid rules, the latter shall take precedence. For the same reason, the call may also be adjusted.
The Research Council may not award aid to an undertaking that has not fulfilled the repayment requirement pursuant to a previous decision by the EFTA Surveillance Authority/the European Commission, which has been declared to be illegal and incompatible with the internal market.
Article 22 of the General Block Exemption Regulation provides, inter alia, that the company
In addition to the requirements above, the Research Council stipulates the following additional requirements:
When assessing the size of the enterprise, the applicant must also take into account the number of employees and the turnover/balance sheet in companies that have an ownership interest of 25 per cent or more in the company, or in which the enterprise itself has an ownership interest of 25 per cent or more. See the definition of SMEs in Annex I of the General Block Exemption Regulation and the EU guide to the SME definition.
The call for proposals has been approved as an aid scheme to the EFTA Surveillance Authority (ESA) with reference 50/2024/SME.
Other requirements relating to the project
The applicant must be aware of the following:
It is important that agreed milestones are reached at the agreed time. This will be given considerable weight when assessing whether the project support should be maintained or whether the contract should be terminated.
Examples of significant reasons that may lead to amendment or termination of the contract are that:
All projects awarded funding under this call are expected to submit a final report and a simplified report no later than one month after the end of the project period.
Start-ups are required to report their accounts annually.
Funding will be disbursed in arrears and only actual costs entered in the institution's accounts will be covered. All reporting shall be done electronically.
For start-up companies, the grant is disbursed based on project account reports for the period to which the costs apply. Project account reports can be submitted continuously throughout the project period.
For other applicants, the grant will be disbursed on the basis of the submitted EHF invoice to the Research Council (non-automatic payment).
This call is open to all disciplines. The Research Council attaches importance to achieving a balanced portfolio of supported projects across sectors and subject areas.
Please note that the application can only be submitted once. If you wish to change the application after it has been submitted, you can create a new application – e.g. as a copy of the already submitted application.
A complete application consists of an application form and mandatory attachments submitted via "My RCN Web".
For more information, see Guidelines for completing the application form and Frequently asked questions about Commercialisation Projects.
If you have previously applied for a commercialisation project and have been rejected, it must be clearly stated at the beginning of the project description what has changed since the previous application.
If you resubmit a previously rejected application without significant changes to the project and the grant application, we will use the original scientific assessment as a basis for further application processing.
Use default templates for all required attachments. These can be downloaded at the bottom of the page.
All attachments to the application must be submitted with the application. We will not accept attachments submitted after the application deadline unless we have requested additional documentation.
We will not consider documents and websites linked to in the application, or attachments other than those specified above. Be careful to upload the correct attachment type, as there are no technical restrictions on what kind of templates it is possible to upload in the application form.
Grant applications will be assessed in the light of the objective of the call and the following criteria:
Assuming all factors relating to quality assessments are equal, priority will be given to:
Grant applications will be assessed by at least two case officers from the Research Council in accordance with the criteria 'Research and innovation', 'Impact and 'Implementation'. The case officers have expertise in the commercialisation of research results and knowledge of relevant technology or areas of application. If the overall average mark for these three criteria is 5 or higher on a scale with 7 as the highest mark, the application will also be assessed on the basis of the criterion 'Relevance to the call for proposals'.
The assessment and marks for all of the assessment criteria will be consolidated into an average mark as an overall expression of the overall assessment of the application.
The administration will then present the applications with their respective marks for the decision. It is the chief executive who is the granting body and makes the final decision on the award.
The Research Council attaches importance to ensuring that the best projects are given priority and that the assessments made are well-founded. The assessments as such are of benefit to applicants as they provide valuable feedback, regardless of whether the project receives support or not.
Please note that if a previously unsuccessful application is resubmitted, without significant changes to the project and the grant application, the original scientific assessment will form the basis for further application processing.
Applications will be assessed and approved on an ongoing basis. You will receive an answer to your application as soon as possible (normally five to six weeks), but no later than three months after submitting your application.
Project no. | Organization | Project title | Subject | Sought | Published |
---|---|---|---|---|---|
356359 | HØGSKOLEN I ØSTFOLD | Advancing Education: Commercialising AI-Driven Essay Assessment Technology (EAT) for Enhanced Teaching and Learning in the 21st Century | Innovasjon | NOK 489 000 | 11.12.2024 |
356356 | HØGSKOLEN I ØSTFOLD | Controlling Energy Harvesting Operation in Wireless Devices (CEHOW) | Innovasjon | NOK 500 000 | 11.12.2024 |
356274 | OSLO UNIVERSITETSSYKEHUS HF | Smartsock: Market needs and user requirements | Innovasjon | NOK 500 000 | 11.12.2024 |
356265 | ARD INNOVATION AS | A digital research-based plant database - a new gold standard for the landscape industry | Innovasjon | NOK 500 000 | 11.12.2024 |
356107 | NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU | A Novel Setup for Surface Characterization of Materials Under Mechanical Stress in Liquid Media | Innovasjon | NOK 500 000 | 11.12.2024 |
356104 | JUSTERVESENET | Commercialisation of a system enabling optical self-calibration | Innovasjon | NOK 500 000 | 11.12.2024 |
355645 | SINTEF TTO AS | MEMS micromirror licensing | Innovasjon | NOK 500 000 | 11.12.2024 |
355636 | NORGES TEKNISK-NATURVITENSKAPELIGE UNIVERSITET NTNU | Early diagnosis of acute kidney injury using ultrasound and artificial intelligence | Innovasjon | NOK 500 000 | 11.12.2024 |
355616 | SINTEF TTO AS | UltraRobo | Innovasjon | NOK 500 000 | 11.12.2024 |
355605 | RAB DIAGNOSTICS AS | A predictive biomarker for Antibody Drug Conjugates in lung cancer | Innovasjon | NOK 500 000 | 11.12.2024 |
355536 | UNIVERSITETET I OSLO | Advanced catalysts production for industrial electrical-to-chemical energy conversion (KataNor) | Innovasjon | NOK 500 000 | 11.12.2024 |
355534 | VALIDÉ AS | T-Wax: New additives for oilfield wax management (WAX) | Innovasjon | NOK 500 000 | 11.12.2024 |
355485 | VESTLANDETS INNOVASJONSSELSKAP AS | NAD replenishment therapy for MS | Innovasjon | NOK 500 000 | 11.12.2024 |
355484 | VESTLANDETS INNOVASJONSSELSKAP AS | Space weather resilience for modern infrastructure | Innovasjon | NOK 500 000 | 11.12.2024 |
355481 | VESTLANDETS INNOVASJONSSELSKAP AS | Next generation imaging for real-time dose verification enabling adaptive proton therapy (NOVO) | Innovasjon | NOK 500 000 | 11.12.2024 |
355476 | UNIVERSITETET I OSLO | The micro diffusimeter (µDiff): a miniaturized simulator accelerating drug development | Innovasjon | NOK 500 000 | 11.12.2024 |
355465 | NORINNOVA AS | High-throughput single sperm microfluidic filter | Innovasjon | NOK 500 000 | 11.12.2024 |
355091 | NORINNOVA AS | mSpider: a universal “digital adaptor” to extract physical activity and health data from wearable sensors | Innovasjon | NOK 500 000 | 11.12.2024 |
355077 | VESTLANDETS INNOVASJONSSELSKAP AS | Forecasting of bipolar episodes | Innovasjon | NOK 500 000 | 11.12.2024 |
355014 | INVEN2 AS | NeoMedSys – Bringing research to the clinic | Innovasjon | NOK 500 000 | 11.12.2024 |
354956 | TECHEP AS | TECHEP - Qualification 2024 | Innovasjon | NOK 500 000 | 11.12.2024 |
354911 | Universitetet i Agder | Autonomous Hooking System (AHS): Enhancing Safety and Efficiency in Lifting and Handling Operations | Innovasjon | NOK 500 000 | 11.12.2024 |
354863 | IN-MOTION TECHNOLOGIES AS | In-Motion AI-based Very Early Cerebral Palsy Detection | Innovasjon | NOK 500 000 | 11.12.2024 |
354858 | VESTLANDETS INNOVASJONSSELSKAP AS | Exploring ebselen Derivatives for Parkinson's Disease Therapy | Innovasjon | NOK 500 000 | 11.12.2024 |
354848 | NABOLAGSHELSE AS | Nabolagshelse.no – A Geographic Information System for Improved Local Health Analytics | Innovasjon | NOK 500 000 | 11.12.2024 |
354824 | VALIDÉ AS | HORCON – next generation extrusion/casting technology | Innovasjon | NOK 500 000 | 11.12.2024 |
354799 | UNIVERSITETET I OSLO | Developing Gene Therapy for Brain Diseases | Innovasjon | NOK 500 000 | 11.12.2024 |
354779 | VESTLANDETS INNOVASJONSSELSKAP AS | CoDesign: Driving innovation in higher education curriculum building and quality assurance through collaborative design and analytics | Innovasjon | NOK 500 000 | 11.12.2024 |
354776 | VALIDÉ AS | Pisces-AI: Physics-Informed AI for Subsurface Characterization ExperimentS | Innovasjon | NOK 500 000 | 11.12.2024 |
354668 | INVEN2 AS | Novel vaccine platform for animal health | Innovasjon | NOK 500 000 | 11.12.2024 |
354651 | UNIVERSITETET I OSLO | muScribe: Automated tranScription of muSic | Innovasjon | NOK 500 000 | 11.12.2024 |
354631 | VESTLANDETS INNOVASJONSSELSKAP AS | Stable Catalysts for Green Chemical Manufacturing | Innovasjon | NOK 500 000 | 11.12.2024 |
354616 | SINTEF TTO AS | The Sometimes Projector | Innovasjon | NOK 500 000 | 11.12.2024 |
354606 | SINTEF TTO AS | ec-Solv Carbon Capture - Qualification Project | Innovasjon | NOK 500 000 | 11.12.2024 |
354588 | INVEN2 AS | Recovery of noble metals lost in high-temperature fertilizer production | Innovasjon | NOK 500 000 | 11.12.2024 |
354572 | VESTLANDETS INNOVASJONSSELSKAP AS | Polar Bear Coating - A new fluor free skiing wax from Bergen, Norway | Innovasjon | NOK 500 000 | 11.12.2024 |
354471 | SINTEF TTO AS | Runway Manager | Innovasjon | NOK 500 000 | 11.12.2024 |
354428 | SINTEF TTO AS | QBeam - low power speaker elements for a green generation | Innovasjon | NOK 500 000 | 11.12.2024 |
354427 | SINTEF TTO AS | Train dispatcher | Innovasjon | NOK 500 000 | 11.12.2024 |
354408 | NTNU TECHNOLOGY TRANSFER AS | The NTNU Bio-nanomachines: Next-generation tools for high-resolution Genomics in Diagnostics and Medical Research | Innovasjon | NOK 500 000 | 11.12.2024 |
354112 | NORD INNOVASJON AS | JUSTscore - Making Connections between Industry and Community in Arctic Sustainable Development | Innovasjon | NOK 500 000 | 11.12.2024 |
354088 | NORINNOVA AS | Multifocus Grating Mirror | Innovasjon | NOK 500 000 | 11.12.2024 |
354065 | UNIVERSITETET I SØRØST-NORGE | Forecasting trends within the maritime industry | Innovasjon | NOK 500 000 | 11.12.2024 |
354037 | VESTLANDETS INNOVASJONSSELSKAP AS | PROCAST35 - a classification test for luminal breast cancer | Innovasjon | NOK 500 000 | 11.12.2024 |
354036 | VESTLANDETS INNOVASJONSSELSKAP AS | CanProX - a protein test for breast cancer hypoxia (33P) relevant for radiation therapy | Innovasjon | NOK 500 000 | 11.12.2024 |
354016 | NORSK REGNESENTRAL | Commercialisation of a beast cancer detection model developed for BreastScreen Norway | Innovasjon | NOK 500 000 | 11.12.2024 |
354013 | VESTLANDETS INNOVASJONSSELSKAP AS | Sustainable and cost-effective supercapacitors | Innovasjon | NOK 500 000 | 11.12.2024 |
353996 | SINTEF DIGITAL | Simulate flow in aortic stent grafts | Innovasjon | NOK 500 000 | 11.12.2024 |
353971 | NTNU TECHNOLOGY TRANSFER AS | Targeted alpha-therapy (TAT) through composition of biocompatible nanoparticles able to carry Ra-223. | Innovasjon | NOK 500 000 | 11.12.2024 |
353902 | SINTEF TTO AS | Photonic 3D | Innovasjon | NOK 500 000 | 11.12.2024 |
353874 | INVEN2 AS | Secretoneurin-related peptides to treat cardiac dysfunction and arrhythmia | Innovasjon | NOK 500 000 | 11.12.2024 |
353869 | INVEN2 AS | An expert radiological system for brain bleed measurement | Innovasjon | NOK 500 000 | 11.12.2024 |
353855 | NORGES GEOTEKNISKE INSTITUTT AS | LaRiMiT - Landslide Risk Mitigation Toolbox | Innovasjon | NOK 500 000 | 11.12.2024 |
353791 | INVEN2 AS | Total analytical solution for enabling robust mass spectrometric analysis of organoids and organ-on-chip samples | Innovasjon | NOK 500 000 | 11.12.2024 |
353759 | Klyv Therapeutics AS | Novel drug candidates for treating heart failure and cardiac fibrosis | Innovasjon | NOK 500 000 | 11.12.2024 |
353597 | SINTEF TTO AS | Ultrasound diagnosis of peripheral lung lesions | Innovasjon | NOK 500 000 | 11.12.2024 |
353596 | INVEN2 AS | p95HER2 Antibody–drug conjugates (ADC) | Innovasjon | NOK 500 000 | 11.12.2024 |
353488 | SMART INNOVATION NORWAY AS | EU Readiness self-assessment tool | Innovasjon | NOK 500 000 | 11.12.2024 |
353448 | INNSIKT.AI. AS | AI-Based Child Avatar for Interview Training | Innovasjon | NOK 500 000 | 11.12.2024 |
353406 | SINTEF TTO AS | MiniCam - Qualification Project | Innovasjon | NOK 500 000 | 11.12.2024 |
353241 | INVEN2 AS | Happy Hands - Hand osteoarthritis therapy App | Innovasjon | NOK 500 000 | 11.12.2024 |
353080 | ARD INNOVATION AS | FUNCHI – Evaluation of production scalability and market potential for new fungal chitosans | Innovasjon | NOK 500 000 | 11.12.2024 |
353004 | INVEN2 AS | Light-assisted cryoprobe for eye surgery | Innovasjon | NOK 500 000 | 11.12.2024 |
352795 | SINTEF TTO AS | Nidaromycin as a drug candidate for treatment of MRSA infections | Innovasjon | NOK 500 000 | 11.12.2024 |
352713 | UNIVERSITETET I SØRØST-NORGE | Iconsume – increased patient safety by prevention of harmful drug-food interactions | Innovasjon | NOK 500 000 | 11.12.2024 |
352712 | SINTEF TTO | Sustainable cultivation of polychaetes as feed in aquaculture | Innovasjon | NOK 500 000 | 11.12.2024 |
352562 | STIFTELSEN NILU | End-to-End Green House Gas (GHG) Monitoring Service | Innovasjon | NOK 500 000 | 11.12.2024 |
352208 | ARD INNOVATION AS | PhosBoard: High-end fibreboards produced with renewable resources and a low energy process. | Innovasjon | NOK 500 000 | 11.12.2024 |
352205 | TYCHO SPACE TECHNOLOGIES AS | Reliability and multi-domain applications in a small satellite onboard processor. | Innovasjon | NOK 500 000 | 11.12.2024 |
352082 | NORINNOVA AS | Computational Adaptive Optics | Innovasjon | NOK 500 000 | 11.12.2024 |
352081 | NTNU TECHNOLOGY TRANSFER AS | The NTNU Lithium-Sulfur Battery | Innovasjon | NOK 500 000 | 11.12.2024 |
352044 | NTNU TECHNOLOGY TRANSFER AS | ProDecs - A software solution for financial analysis under uncertainty: contributing to better investment decisions in complex projects. | Innovasjon | NOK 500 000 | 11.12.2024 |
352038 | NORINNOVA AS | CDK7 radiopharmaceutical development for improved diagnostics of glioblastoma with Positron Emission Tomography (PET) | Innovasjon | NOK 500 000 | 11.12.2024 |
351997 | INVEN2 AS | Software for optimizing accessibility and memorability of text in marketing and communication | Innovasjon | NOK 500 000 | 11.12.2024 |
351996 | VALIDÉ AS | PigStick - Diagnostic of bacterial-caused lameness in pigs | Innovasjon | NOK 500 000 | 11.12.2024 |
351994 | INVEN2 AS | Switch receptor for use in adoptive cell therapy | Innovasjon | NOK 500 000 | 11.12.2024 |
351955 | VALIDÉ AS | Optimizing Manufacturing Efficiency with AISToolbox | Innovasjon | NOK 500 000 | 11.12.2024 |
351945 | INVEN2 AS | Confirming commercial feasibility of a superior endotoxin detection assay | Innovasjon | NOK 346 000 | 11.12.2024 |
351915 | INVEN2 AS | Development of CAR-T therapy to treat ovarian cancer | Innovasjon | NOK 500 000 | 11.12.2024 |
351914 | INVEN2 AS | Glyco-specific antibodies and CAR-T for therapy and diagnostics of solid tumors | Innovasjon | 500 000 | 11.12.2024 |
Messages at time of print 20 June 2025, 10:07 CEST